Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Australia backs Pfizer virus vaccine over AstraZeneca for under-50s

04/07/2021 | 09:20pm EDT

* Policy shift will hold up vaccination campaign, says PM

* People with first shot should still get their second

* Italy, UK have suggested AstraZeneca shot age limits (Adds quote from chief health officer, prime minister and adds detail)

CANBERRA/SYDNEY, April 8 (Reuters) - Australia said on Thursday it now recommends people under 50 should get Pfizer's COVID-19 vaccine in preference to AstraZeneca's shot, a policy shift that it warned would hold up its inoculation campaign.

The move, a day after European regulators reiterated they had found possible links between AstraZeneca's shot and reports of very rare cases of blood clots, is a huge hurdle for Australia's programme, which had relied on that vaccine.

Australia's Chief Medical Officer, Paul Kelly, told reporters the risk of clots was extremely low.

"It's only been found in the first dose of the AstraZeneca vaccine, usually within 4 to 10 days after that vaccine. But it is serious, and it can cause up to a 25% death rate when it occurs," he said.

Australia would advise health providers to only give a first dose of the AstraZeneca vaccine to adults younger than 50 when the benefit clearly outweighs the risks, he added.

Italy and Britain on Wednesday joined other countries in suggesting age limits for AstraZeneca's vaccine. But the European regulators reaffirmed the importance of that shot in protecting people against COVID-19.

Those who have already had a first AstraZeneca dose without any serious adverse events "can safely be given their second dose," Kelly said.

Prime Minister Scott Morrison said the updated advice will delay Australia's inoculation timetable, but it was too soon to say when Canberra would now vaccinate its adult population.

"There will be a recalibration of how the programme will need to be adjusted," Morrison told reporters in Canberra.

Australia has ordered 20 million doses of the Pfizer vaccine and Morrison said Canberra was in talks to increase the order.

Authorities will continue to give the AstraZeneca vaccine to people over 70. Those over 50 who opt for the Pfizer vaccine will have to wait, the government said.

Australia - which had planned to use the AstraZeneca vaccine for the vast majority of its near 26 million population - expected to give all adults at least one shot by October.

But its immunisation campaign was already heavily behind schedule.

It had pledged to administer at least 4 million first doses by the end of March, but could only deliver 670,000, with the government blaming the delay on supply issues in Europe.

It had been looking to ramp up the immunisation effort, underpinned by plans to make 50 million doses of AstraZeneca vaccine in Australia, produced by CSL Ltd.

Australia began vaccinations much later than some other nations because of its few infections, which stand at just under 29,400, with 909 deaths, since the pandemic began.

(Global vaccination tracker: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access/)

(Interactive graphic tracking global spread of coronavirus: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/)

(Reporting by Colin Packham and Jonathan Barrett; Editing by Michael Perry, Clarence Fernandez and Andrew Heavens)

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.85% 7225 Delayed Quote.-0.51%
CSL LIMITED 0.80% 265.5 End-of-day quote.-6.24%
All news about ASTRAZENECA PLC
12:29pTHE LATEST : CDC head warns against surging shots to Michigan
12:08pLONDON STOCK EXCHANGE : FTSE 100 ends lower as miners track lower metal prices; ..
10:25aASTRAZENECA  : Argus Research Downgrades AstraZeneca to Hold From Buy
09:35aASTRAZENECA  : Ireland set to restrict use of AstraZeneca vaccine -RTE
09:33aAustralia Expects Big Delays to Vaccine Rollout
09:02aBulgarian PM reveals price for EU's new vaccine contract with Pfizer
08:54aASTRAZENECA  : Indian panel gives emergency approval for Russia's Sputnik V vacc..
08:35aASTRAZENECA  : Brazil, Mexico, Philippines among those due to get Pfizer shots f..
08:00aSpain expects first batch of single-dose Janssen shot within 48 hours
07:26aEUROPE ECONOMICS : Action Economics on The UK Week Ahead; COVID-19 Vaccine Rollo..
More news
Financials (USD)
Sales 2021 30 893 M - -
Net income 2021 4 586 M - -
Net Debt 2021 14 367 M - -
P/E ratio 2021 27,7x
Yield 2021 2,86%
Capitalization 131 B 131 B -
EV / Sales 2021 4,71x
EV / Sales 2022 4,06x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 130,05 $
Last Close Price 99,88 $
Spread / Highest target 66,2%
Spread / Average Target 30,2%
Spread / Lowest Target -5,71%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-0.51%131 272
JOHNSON & JOHNSON2.46%424 524
ROCHE HOLDING AG0.21%288 043
PFIZER, INC.-0.57%204 161
NOVARTIS AG-3.29%197 172
MERCK & CO., INC.-6.71%193 164